EarlyCDT®ImmunoINSIGHTSWHO predicts 16.4M deaths from cancer globally by 2040, up from 9.6M in 2018. This is equivalent to almost a quarter of the British population every year.We need this blood test across the UK. It’s saved my life, and everyone should have it. It will save so many lives.Rebecca. Glasgow, ScotlandWe need this blood test across the UK. It’s saved my life, and everyone should have it. It will save so many lives.Rebecca. Glasgow, ScotlandCancer drug trials using biomarkers are 6.7 times more likely to be approved for use.Today, only 12% of cancer patients in the US benefit from the transformative, approved immunotherapies.I couldn't believe it when they told me I had lung cancer. I was out of hospital just a week after the operation.Wilma. Wishaw, ScotlandI couldn't believe it when they told me I had lung cancer. I was out of hospital just a week after the operation.Wilma. Wishaw, ScotlandWe understand disease through the lens of the human immune system, to enable early detection and better treatment of cancer.Extra TimeEvent—10 Feb 2020Extra Time exhibition10 Feb 2020Our campaign to get approval for a nationwide lung cancer screening programme.EventLatest@OncimmuneECDTProf Ola Winqvist, Professor of Cellular Immunotherapy the Karolinska Institute speaks with Dr Adam M Hill on Extra TimeOpen external linkTweet—05 Jul 2020Oncimmune submission to Health and Social Care Committee inquiryArticle—29 Jan 2020Diagnostics: why are they now getting the attention they deserve?Article—10 May 2020Has this doctor revolutionised lung cancer detection?Article—02 Nov 2019Presentation at the Shares & AJ Bell investor eveningShares Spotlight webinars feature presentations from directors of listed companies explaining their investment propositions followed by an opportunity for you to ask questions.Event—08 Jul 2020@OncimmuneECDTOncimmune and Medicines Discovery Catapult awarded funding for COVID-19 researchOpen external linkTweet—05 Jul 2020EarlyCDT Lung for cancer risk classification of indeterminate pulmonary nodules.NICE Medtech Innovation Briefing on EarlyCDT LungOpen external linkPublication—17 Mar 2020@OncimmuneECDTCEO, Dr Adam M Hill appointed onto the ABHI board of directorsOpen external linkTweet—17 Jul 2020@OncimmuneECDT“I didn’t have a cough. I could walk for miles. I had none of the signs. The test showed I had #cancer and I was offered an operation. They removed the cancer and a bit of my left lung. It saved my life."Open external linkTweet—06 Jul 2020@OncimmuneECDT“By backing this pioneering project, we are ensuring that the best therapeutic approaches can be offered to the right patients at the right time.” Business Secretary, Alok SharmaOpen external linkTweet—20 Jul 2020Webinar: The utility of autoantibodies in immuno-oncologyNovel biomarkers of immunotherapy outcomes and immune-related adverse events.Event—10 Sep 2020@OncimmuneECDT‘Diagnostics: Recovery and Renewal’, released last week by Sir Mike Richards as part of NHS Long Term Plan lays out the need for new service models to provide safe, patient-centred diagnostic pathways.Open external linkTweet—26 Nov 2020@OncimmuneECDT3 reasons to add Oncimmune to your VOXmarkets watchlistOpen external linkTweet—29 Jun 2020@OncimmuneECDT"We all know the prime directive in medicine to first do no harm, and now as therapies become more complicated and technologies more advanced, we may have the opportunity to predict and prevent toxicity instead of watch and react" Dr Scott Chandler, RocheOpen external linkTweet—07 Jul 2020'Extra Time' podcast in conversation with Dr Melanie LeeArticle—02 Sep 2020'Extra Time' podcast in conversation with Professor Chris MolloyArticle—04 Oct 2020'Extra Time' podcast in conversation with Dr Ian CampbellArticle—05 Aug 2020@OncimmuneECDT"We are delighted to be partnering with such a progressive and respected organisation as Augmenta on this important programme... and once again, utilising our infectious diseases panel to help support the fight against COVID-19" Dr Adam M HillOpen external linkTweet—26 Nov 2020Diagnostics: why are they now getting the attention they deserve?Article—10 May 2020@OncimmuneECDTOncimmune and Medicines Discovery Catapult awarded funding for COVID-19 researchOpen external linkTweet—05 Jul 2020@OncimmuneECDT“I didn’t have a cough. I could walk for miles. I had none of the signs. The test showed I had #cancer and I was offered an operation. They removed the cancer and a bit of my left lung. It saved my life."Open external linkTweet—06 Jul 2020@OncimmuneECDT‘Diagnostics: Recovery and Renewal’, released last week by Sir Mike Richards as part of NHS Long Term Plan lays out the need for new service models to provide safe, patient-centred diagnostic pathways.Open external linkTweet—26 Nov 2020'Extra Time' podcast in conversation with Dr Melanie LeeArticle—02 Sep 2020@OncimmuneECDT"We are delighted to be partnering with such a progressive and respected organisation as Augmenta on this important programme... and once again, utilising our infectious diseases panel to help support the fight against COVID-19" Dr Adam M HillOpen external linkTweet—26 Nov 2020@OncimmuneECDTProf Ola Winqvist, Professor of Cellular Immunotherapy the Karolinska Institute speaks with Dr Adam M Hill on Extra TimeOpen external linkTweet—05 Jul 2020Has this doctor revolutionised lung cancer detection?Article—02 Nov 2019EarlyCDT Lung for cancer risk classification of indeterminate pulmonary nodules.NICE Medtech Innovation Briefing on EarlyCDT LungOpen external linkPublication—17 Mar 2020@OncimmuneECDT“By backing this pioneering project, we are ensuring that the best therapeutic approaches can be offered to the right patients at the right time.” Business Secretary, Alok SharmaOpen external linkTweet—20 Jul 2020@OncimmuneECDT3 reasons to add Oncimmune to your VOXmarkets watchlistOpen external linkTweet—29 Jun 2020'Extra Time' podcast in conversation with Professor Chris MolloyArticle—04 Oct 2020Oncimmune submission to Health and Social Care Committee inquiryArticle—29 Jan 2020Presentation at the Shares & AJ Bell investor eveningShares Spotlight webinars feature presentations from directors of listed companies explaining their investment propositions followed by an opportunity for you to ask questions.Event—08 Jul 2020@OncimmuneECDTCEO, Dr Adam M Hill appointed onto the ABHI board of directorsOpen external linkTweet—17 Jul 2020Webinar: The utility of autoantibodies in immuno-oncologyNovel biomarkers of immunotherapy outcomes and immune-related adverse events.Event—10 Sep 2020@OncimmuneECDT"We all know the prime directive in medicine to first do no harm, and now as therapies become more complicated and technologies more advanced, we may have the opportunity to predict and prevent toxicity instead of watch and react" Dr Scott Chandler, RocheOpen external linkTweet—07 Jul 2020'Extra Time' podcast in conversation with Dr Ian CampbellArticle—05 Aug 2020
